Form 4: Windtree Therapeutics Executive Acquires Preferred Stock and Warrants

SVP and Chief Medical Officer of Windtree Therapeutics, Steven Simonson, reports acquisition of Series C Preferred Stock and warrants in a private placement.

Summary

• Steven Simonson, SVP and Chief Medical Officer of Windtree Therapeutics, filed a Form 4 disclosing changes in beneficial ownership.
• On July 22, 2024, Simonson acquired 13 shares of Series C Convertible Preferred Stock in a private placement.
• The Series C Preferred Stock has a stated value of $1,000 per share and a conversion price of $3.74 per share.
• Simonson also acquired 2,674 warrants to purchase common stock at an exercise price of $4.11 per share.
• The warrants become exercisable six months and one day after the issuance date and expire five years after the initial exercisability date.
• Following the reported transactions, Simonson directly owns 13 shares of Series C Preferred Stock and 2,674 warrants, as well as 3,471 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and warrants by an executive could signal confidence, but it's a routine filing and doesn't provide strong directional information.

Positives

• The acquisition of preferred stock and warrants by a key executive could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. They provide transparency into insider transactions.

Stakeholder Impact

• The acquisition of shares by an executive may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, beneficial ownership, Windtree Therapeutics, WINT, Series C Preferred Stock, warrants, Steven Simonson, private placement